written on 01.05.2014
Tags:
,

Novartis sees brain-atrophy data as an edge for MS pill Gilenya

TAGS: ,

Fresh off winning European backing for broader use–which could prompt more multiple sclerosis patients to switch–Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.

Latest Report